Real-world effectiveness and safety of risankizumab induction and maintenance therapy in pediatric patients with Crohn's disease: a multicenter retrospective analysis. (PubMed, J Crohns Colitis) - Oct 1, 2026 - "In this multicenter pediatric cohort, risankizumab induced meaningful clinical and biomarker improvement with durable remission and a favorable safety profile, supporting risankizumab as an effective option for children with CD."
Journal • Real-world evidence • Retrospective data • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease • Pediatrics • CRP
|
|
Amit Assa; Chani Topf-Olivestone; Christos Tzvinikos; Dan Turner; Dror S Shouval; Elizabeth A Spencer; Eyal Zifman; Firas Rinawi; Lauren V Collen; Marla C Dubinsky; Mordechai Slae; Quentin Buck; Raffi Lev-Tzion; Richard K Russell; Ronen Stein; Tyler Babinski
|